Confirmation by exome sequencing of the pathogenic role of NCSTN mutations in acne inversa (hidradenitis suppurativa).

1] Department of Dermatology, Institute of Dermatology, No. 1 Hospital, Anhui Medical University, Anhui, China [2] State Key Laboratory Incubation Base of Dermatology, Ministry of National Science and Technology, Anhui, China [3] These authors contributed equally to this work.
Journal of Investigative Dermatology (Impact Factor: 6.19). 03/2011; 131(7):1570-2. DOI: 10.1038/jid.2011.62
Source: PubMed
  • Journal of dermatological science 01/2014; · 3.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The advent of whole-exome sequencing (WES) has facilitated the discovery of rare structure and functional genetic variants. Combining exome sequencing with linkage studies is one of the most efficient strategies in searching disease genes for Mendelian diseases. WES has achieved great success in the past three years for Mendelian disease genetics and has identified over 150 new Mendelian disease genes. We illustrate the workflow of exome capture and sequencing to highlight the advantages of WES. We also indicate the progress and limitations of WES that can potentially result in failure to identify disease-causing mutations in part of patients. With an affordable cost, WES is expected to become the most commonly used tool for Mendelian disease gene identification. The variants detected cumulatively from previous WES studies will be widely used in future clinical services.
    Frontiers of medicine. 01/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Genomics has revolutionized the study of rare diseases. In this review, we overview the latest technological development, rare disease discoveries, implementation obstacles and bioethical challenges. First, we discuss the technology of genome and exome sequencing, including the different next-generation platforms and exome enrichment technologies. Second, we survey the pioneering centers and discoveries for rare diseases, including few of the research institutions that have contributed to the field, as well as an overview survey of different types of rare diseases that have had new discoveries due to next-generation sequencing. Third, we discuss the obstacles and challenges that allow for clinical implementation, including returning of results, informed consent and privacy. Last, we discuss possible outlook as clinical genomics receives wider adoption, as third-generation sequencing is coming onto the horizon, and some needs in informatics and software to further advance the field.
    Expert Review of Molecular Diagnostics 04/2014; · 4.09 Impact Factor